Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
A Comprehensive Review of dermatan sulfate's R&D Innovations and Drug Target Mechanism
Drug Insights
5 min read
A Comprehensive Review of dermatan sulfate's R&D Innovations and Drug Target Mechanism
13 October 2023
This article summarized the latest R&D progress of dermatan sulfate, the Mechanism of Action for dermatan sulfate, and the drug target R&D trends for dermatan sulfate.
Read →
Vertex shares results of Phase 1/2 trial of VX-880 for Type 1 Diabetes
Latest Hotspot
3 min read
Vertex shares results of Phase 1/2 trial of VX-880 for Type 1 Diabetes
13 October 2023
Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.
Read →
Pharmaceutical Insights: darifenacin hydrobromide's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
5 min read
Pharmaceutical Insights: darifenacin hydrobromide's R&D Progress and its Mechanism of Action on Drug Target
13 October 2023
This article summarized the latest R&D progress of darifenacin hydrobromide, the Mechanism of Action for darifenacin hydrobromide, and the drug target R&D trends for darifenacin hydrobromide.
Read →
Preliminary Findings from NT219 Phase 1/2 Trial in Head & Neck Cancer Announced by Purple Biotech
Latest Hotspot
4 min read
Preliminary Findings from NT219 Phase 1/2 Trial in Head & Neck Cancer Announced by Purple Biotech
13 October 2023
Purple Biotech Ltd. shares clinical insights from its dose amplification segment of the Phase 1/2 trial of NT219.
Read →
Interpretation of Endpoint Data for Clinical Trials on Tumors
Knowledge Base
8 min read
Interpretation of Endpoint Data for Clinical Trials on Tumors
13 October 2023
The most commonly used efficacy endpoints in clinical trials of anti-tumor drugs are Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS), among others.
Read →
Ocular Therapeutix™ Initiates its Premier Vital Clinical Study for OTX-TKI
Latest Hotspot
3 min read
Ocular Therapeutix™ Initiates its Premier Vital Clinical Study for OTX-TKI
13 October 2023
Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.
Read →
Exploring cysteamine hydrochloride's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring cysteamine hydrochloride's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
13 October 2023
This article summarized the latest R&D progress of cysteamine hydrochloride, the Mechanism of Action for cysteamine hydrochloride, and the drug target R&D trends for cysteamine hydrochloride.
Read →
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment Abilities with Advanced Radioligand Therapies
Latest Hotspot
3 min read
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment Abilities with Advanced Radioligand Therapies
13 October 2023
Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.
Read →
What is Time To Progression (TTP) and Time To Treatment Failure (TTF) in clinical trials?
"What" Series
2 min read
What is Time To Progression (TTP) and Time To Treatment Failure (TTF) in clinical trials?
13 October 2023
TTF, in comparison to PFS, synthesizes the effectiveness and safety characteristics of the drug, encompasses treatment failure for any reason and includes death.
Read →
Decoding cyclizine hydrochloride: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding cyclizine hydrochloride: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
13 October 2023
This article summarized the latest R&D progress of cyclizine hydrochloride, the Mechanism of Action for cyclizine hydrochloride, and the drug target R&D trends for cyclizine hydrochloride.
Read →
What is Disease Free Survival (DFS) and Event Free Survival (EFS) in clinical trials?
"What" Series
2 min read
What is Disease Free Survival (DFS) and Event Free Survival (EFS) in clinical trials?
13 October 2023
Event-Free Survival (EFS), compared to Disease-Free Survival (DFS), adds a surgical intervention criterion and is often used to evaluate neoadjuvant therapy pre-surgery, or radiotherapy.
Read →
Alvotech Signs Exclusive License Contract with Kashiv BioSciences for Marketing of Xolair®
Latest Hotspot
3 min read
Alvotech Signs Exclusive License Contract with Kashiv BioSciences for Marketing of Xolair®
13 October 2023
Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).
Read →